Novel Experimental Therapies for Treatment of Pulmonary Arterial Hypertension
| Autor: | Ronald Zolty |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
Disease Review Vascular remodelling in the embryo Pathogenesis Right heart failure new drug targets Internal medicine pulmonary hypertension Medicine Pharmacology (medical) Pulmonary hemodynamics Pharmacology clinical trials business.industry toxicity investigational drugs vascular remodelling medicine.disease Pulmonary hypertension animal models Clinical trial medicine.anatomical_structure Vascular resistance Cardiology Molecular Medicine business |
| Zdroj: | Journal of Experimental Pharmacology |
| ISSN: | 1179-1454 |
| Popis: | Pulmonary arterial hypertension (PAH) is a progressive and devastating disease characterized by pulmonary artery vasoconstriction and vascular remodeling leading to vascular rarefaction with elevation of pulmonary arterial pressures and pulmonary vascular resistance. Often PAH will cause death from right heart failure. Current PAH-targeted therapies improve functional capacity, pulmonary hemodynamics and reduce hospitalization. Nevertheless, today PAH still remains incurable and is often refractory to medical therapy, underscoring the need for further research. Over the last three decades, PAH has evolved from a disease of unknown pathogenesis devoid of effective therapy to a condition whose cellular, genetic and molecular underpinnings are unfolding. This article provides an update on current knowledge and summarizes the progression in recent advances in pharmacological therapy in PAH. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
| Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |